跳至主要内容
临床试验/NL-OMON50704
NL-OMON50704已完成4 期

Memory response against Bordetella pertussis in adults: immunological effects of an acellular pertussis booster vaccination - VIKING-study

RIVM0 个研究点目标入组 106 人开始时间: 待定最近更新:
适应症

试验速览

阶段
4 期
状态
已完成
发起方
入组人数
106

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 99(—)

入选标准

  • In order to be eligible to participate in this study, participants must meet
  • all of the following criteria:
  • Good general health;
  • 25-29 years of age;
  • Vaccinated with DTwP-IPV (RIVM) at 3, 4, 5, and 11 months of age;
  • Received all other regular vaccines according to the Dutch NIP;
  • Provision of written informed consent;
  • Adherent to protocol and available during the study period.

排除标准

  • Any of the following criteria will exclude a participant from this study:
  • Antibiotic use within 14 days of enrollment;
  • Present evidence of serious disease(s) demanding immunosuppressive medical
  • treatment, like corticosteroids, that might interfere with the results of the
  • study within the last 3 months;
  • Known or suspected allergy to any of the vaccine components (by medical
  • Occurrence of serious adverse event after primary DTwP-IPV vaccination or
  • other vaccination (by medical history);
  • Known or suspected immune deficiency;
  • History of any neurologic disorder, including epilepsy;
  • Previous administration of serum products (including immunoglobulins) within
  • 6 months before vaccination and blood/ saliva sampling;
  • Vaccination with any other pertussis vaccine than those described in the
  • inclusion criteria;
  • No DT or DT-IPV vaccination at least 5 years before enrollment;
  • Vaccination within a month before enrollment;
  • Pregnant at start of study (when vaccination is administered);

研究者

发起方
RIVM

相似试验